Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ExelixisMIL:1EXEL 74 EV-to-EBITDA is 12.61 as of Aug. 20, 2026, which is 20% below its 10-year median of 15.82. GuruFocus rates MIL:1EXEL with a GF Score™ of 74/100 and a GF Value™ of €40.82 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 402 Biotechnology companies, Exelixis ranks better than 53.98% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Exelixis's enterprise value is €11,060 Mil.
Exelixis's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €877 Mil. Therefore, Exelixis's EV-to-EBITDA for today is 12.61.
The historical rank and industry rank for Exelixis's EV-to-EBITDA or its related term are showing as below:
MIL:1EXEL'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -177.8 Med: 15.82 Max: 206.87
Current: 12.55
During the past 13 years, the highest EV-to-EBITDA of Exelixis was 206.87. The lowest was -177.80. And the median was 15.82.
MIL:1EXEL's EV-to-EBITDA is ranked better than 53.98% of 402
companies
in the Biotechnology industry
Industry Median: 14.41
vs MIL:1EXEL: 12.55
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Exelixis's share price for today is €45.895.
Exelixis's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.735.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Exelixis's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:1EXEL vs MDGL, AXSM, ARWR: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Exelixis's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Exelixis EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Exelixis's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Exelixis's EV-to-EBITDA falls into.
Exelixis's current Enterprise Value is €11,060 Mil.
Exelixis's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €877 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Exelixis (MIL:1EXEL) has a EV-to-EBITDA of 12.61 as of Aug. 20, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Exelixis. This is 20% below median its historical median of 15.82. According to the industry distribution chart, Exelixis ranks #185 out of 402 companies in the Biotechnology industry, placing it in the top 46%.
Is Exelixis' EV-to-EBITDA too high?
Exelixis' current EV-to-EBITDA of 12.61 is 20% below median its 10-year median of 15.82. The Biotechnology industry median EV-to-EBITDA is 14.41. Exelixis' value of 12.61 is 12.5% below this industry median. Based on the distribution chart, Exelixis ranks #185 out of 402 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Exelixis has a GF Score™ of 74/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Exelixis' EV-to-EBITDA compare to MDGL and AXSM?
According to the Biotechnology industry distribution chart, Exelixis ranks #185 out of 402 companies for EV-to-EBITDA. This puts Exelixis in the upper half of its industry. The industry median EV-to-EBITDA is 14.41. Exelixis' value of 12.61 is 12.5% below this benchmark. While the company's 10-year median is 15.82 vs. the industry median of 14.41, Exelixis has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 14.41, based on 402 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Exelixis's current EV-to-EBITDA of 12.61 is 12.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Exelixis. For the Biotechnology industry, the median EV-to-EBITDA is 14.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Exelixis's current EV-to-EBITDA is 12.61, which is 20% below median its own 10-year median of 15.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exelixis stock overvalued right now?
Based on GuruFocus' analysis, Exelixis (MIL:1EXEL) is currently considered Modestly Overvalued. The stock's GF Value™ is €40.82, compared to a current price of €45.90 — trading 12.4% above its estimated fair value. The current EV-to-EBITDA is 12.61, which is 20% below median its 10-year median of 15.82 and 12.5% below the Biotechnology industry median of 14.41. Exelixis' overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Exelixis (MIL:1EXEL), the current EV-to-EBITDA is 12.61 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Exelixis (MIL:1EXEL) Overvalued in 2026?
Based on GuruFocus' analysis, Exelixis stock appears to be overvalued.
The current stock price of €45.90 is trading 12.4% above its estimated GF Value™ of €40.82.
GuruFocus considers Exelixis to be Modestly Overvalued.
Key valuation signals for MIL:1EXEL:
EV-to-EBITDA: 12.61 (20% below median its 10-year median of 15.82)
GF Value™: €40.82 vs. price of €45.90 (12.4% above fair value)
Industry Position: 12.5% below the Biotechnology median (#185 of 402)
No single metric tells the full story. See the MIL:1EXEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
74GF Score
Get the complete analysis for MIL:1EXEL
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:1EXEL has been successfully added to your 
